250 related articles for article (PubMed ID: 34382412)
1. OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
Gaspar N; Campbell-Hewson Q; Huang J; Okpara CE; Bautista F
Future Oncol; 2021 Nov; 17(32):4249-4261. PubMed ID: 34382412
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
[TBL] [Abstract][Full Text] [Related]
4. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Xiao X; Wang W; Wang Z
Paediatr Drugs; 2014 Dec; 16(6):503-12. PubMed ID: 25392156
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.
Gentet JC; Brunat-Mentigny M; Demaille MC; Pein F; Avet-Loiseau H; Berger C; De Lumley L; Pacquement H; Schmitt C; Sariban E; Pillon P; Bernard JL; Kalifa C
Eur J Cancer; 1997 Feb; 33(2):232-7. PubMed ID: 9135494
[TBL] [Abstract][Full Text] [Related]
6. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
Goorin AM; Harris MB; Bernstein M; Ferguson W; Devidas M; Siegal GP; Gebhardt MC; Schwartz CL; Link M; Grier HE
J Clin Oncol; 2002 Jan; 20(2):426-33. PubMed ID: 11786570
[TBL] [Abstract][Full Text] [Related]
7. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
8. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
9. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
[TBL] [Abstract][Full Text] [Related]
10. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
11. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up.
Aznab M; Hematti M
J Cancer Res Ther; 2017; 13(2):291-296. PubMed ID: 28643750
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
16. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F
Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
